Table 4.
Therapeutic interventions in patients with sepsis and NeOAF
| NeOAF patients (n = 240) | P value | |||
|---|---|---|---|---|
| Overall (n = 240) | NeOAF to SR (n = 165) | NeOAF to AF (n = 75) | ||
| Pharmacological, n (%) | ||||
| Amiodarone | 80 (33.3) | 52 (31.5) | 28 (37.3) | 0.38 |
| Beta-blockers | 88 (36.7) | 67 (40.6) | 21 (28.0) | 0.06 |
| Non-DHP CCBsa | 66 (27.5) | 47 (28.5) | 19 (25.3) | 0.61 |
| Digoxin glycosides | 27 (11.3) | 15 (9.1) | 12 (16.0) | 0.12 |
| Electrical cardioversion, n (%) | 8 (3.3) | 4 (2.4) | 4 (5.3) | 0.25 |
NeOAF new-onset atrial fibrillation, AF atrial fibrillation, SR sinus rhythm. aOnly indicates non-dihydropyridine calcium channel blockers (non-DHP CCBs)